Jilin Aodong Pharmaceutical Group Management

Management criteria checks 3/4

Jilin Aodong Pharmaceutical Group's CEO is Shuqin Guo, appointed in Jul 2017, has a tenure of 6.83 years. directly owns 0.14% of the company’s shares, worth CN¥24.78M. The average tenure of the management team and the board of directors is 6.8 years and 6.8 years respectively.

Key information

Shuqin Guo

Chief executive officer

CN¥2.4m

Total compensation

CEO salary percentage	n/a
CEO tenure	6.8yrs
CEO ownership	0.1%
Management average tenure	6.8yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Apr 23

CEO

Shuqin Guo (60 yo)

6.8yrs

Tenure

CN¥2,406,900

Compensation

Ms. Shuqin Guo serves Vice Chairman and General Manager of Jilin Aodong Pharmaceutical Group Co., Ltd. (formerly known as Jilin Aodong Medicine Industry Group Co., Ltd) since July 17, 2017.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shuqin Guo	Vice Chairman & GM	6.8yrs	CN¥2.41m	0.14% CN¥ 24.8m
Shuyuan Zhang	CFO, Deputy GM & Director	6.8yrs	CN¥278.90k	0.013% CN¥ 2.3m
Kai Yang	Deputy GM & Director	6.8yrs	CN¥298.80k	0.013% CN¥ 2.3m
Zhen Yu Wang	Deputy GM	2.3yrs	CN¥229.90k	0.0085% CN¥ 1.5m

6.8yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 000623's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shuqin Guo	Vice Chairman & GM	6.8yrs	CN¥2.41m	0.14% CN¥ 24.8m
Shuyuan Zhang	CFO, Deputy GM & Director	6.8yrs	CN¥278.90k	0.013% CN¥ 2.3m
Kai Yang	Deputy GM & Director	6.8yrs	CN¥298.80k	0.013% CN¥ 2.3m
Zhen Yu Wang	Deputy GM	6.8yrs	CN¥229.90k	0.0085% CN¥ 1.5m
Xiulin Li	Chairman	31.3yrs	CN¥3.01m	0.28% CN¥ 48.0m
Yongfeng Chen	Chief Supervisor	6.8yrs	CN¥701.50k	0.013% CN¥ 2.3m
Yan Bi	Independent Director	6.8yrs	CN¥67.30k	no data
Yuju Sun	Member of Supervisory Board	16yrs	CN¥10.00k	no data
Dalong Zhao	Director	3.8yrs	CN¥228.90k	0.0061% CN¥ 1.1m
Biming Liang	Independent Director	less than a year	no data	no data
Peng Li	Independent Director	3.8yrs	CN¥103.80k	no data
Weiwei Xiao	Independent Director	3.8yrs	CN¥103.80k	no data

6.8yrs

Average Tenure

51yo

Average Age

Experienced Board: 000623's board of directors are considered experienced (6.8 years average tenure).

Jilin Aodong Pharmaceutical Group Management

Management criteria checks 3/4

Key information

Recent management updates

Jilin Aodong Pharmaceutical Group Co., Ltd., Annual General Meeting, May 17, 2024

Jilin Aodong Pharmaceutical Group Co., Ltd. Elects Liang Biming as Independent Director

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.43 in 1Q 2023)

There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Jilin Aodong Pharmaceutical Group Co., Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS misses analyst expectations

Jilin Aodong Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Jilin Aodong Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 17, 2024

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.57 in 3Q 2022)

Jilin Aodong Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) announces an Equity Buyback for CNY 150 million worth of its shares.

Second quarter 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.40 in 2Q 2022)

Jilin Aodong Pharmaceutical Group Co., Ltd. Elects Liang Biming as Independent Director

Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023

Jilin Aodong Pharmaceutical Group Co., Ltd Approves the Profit Distribution Proposal for 2022

Full year 2022 earnings released: EPS: CN¥1.57 (vs CN¥1.56 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.51 in 2Q 2021)

Jilin Aodong Pharmaceutical Group Co., Ltd. Implements Cash Dividend, Payable on 16 June 2022

Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend for 2021

Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) announces an Equity Buyback for CNY 300 million worth of its shares.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.42 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.50 (vs CN¥0.60 in 2Q 2020)

Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥1.48 (vs CN¥1.21 in FY 2019)

Jilin Aodong Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Apr 17, 2021

New 90-day low: CN¥15.60

New 90-day low: CN¥16.01

New 90-day low: CN¥16.27

New 90-day low: CN¥16.57

Third quarter earnings released

Jilin Aodong Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age